Erythropoietin decreases carbon tetrachloride-induced hepatic fibrosis by inhibiting transforming growth factor-beta

Chinese Medical Journal

Volumn 125, Issue 17, 2012, Pages 3098-3103

  Park, Soo Young ^a   Lee, Joo Young ^a   Tak Prof , Won Young ^a   Kweon, Young Oh ^a   Lee, Mi Suk ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Animal model; Erythropoietin; Fibrosis; Hepatic stellate cell; Transforming growth factor beta

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CARBON TETRACHLORIDE; ERYTHROPOIETIN RECEPTOR; FIBRONECTIN; RECOMBINANT ERYTHROPOIETIN; SMAD PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL;

ANIMALS; CARBON TETRACHLORIDE; CELLS, CULTURED; ERYTHROPOIETIN; FIBRONECTINS; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84866104387     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.17.024     Document Type: Article

References (16)

1. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529.
2. Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53.
3. Baroni GS, Pastorelli A, Manzin A, Benedetti A, Marucci L, Solforosi L, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999; 19: 212-219.
4. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21: 397-416.
5. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
6. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96: 12719-12724.
7. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14 Suppl 2: 22-28.
8. Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 2007; 18: 1497-1507.
9. Schmeding M, Boas-Knoop S, Lippert S, Ruehl M, Somasundaram R, Dagdelen T, et al. Erythropoietin promotes hepatic regeneration after extended liver resection in rats. J Gastroenterol Hepatol 2008; 23: 1125-1131.
10. Wen TC, Sadamoto Y, Tanaka J, Zhu PX, Nakata K, Ma YJ, et al. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 2002; 67: 795-803.
11. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007.
12. Kwon TH, Nielsen J, Masilamani S, Hager H, Knepper MA, Frokiaer J, et al. Regulation of collecting duct AQP3 expression: response to mineralocorticoid. Am J Physiol Renal Physiol 2002; 283: F1403-F1421.
13. Paquet KJ, Kamphausen U. The carbon-tetrachloridehepatotoxicity as a model of liver damage. First report: Long-time biochemical changes. Acta Hepatogastroenterol (Stuttg) 1975; 22: 84-88.
14. Li X, Meng Y, Yang XS, Mi LF, Cai SX. ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2,9. World J Gastroenterol 2005; 11: 4807-4811.
15. Chae HB, Jang LC, Park SM, Son BR, Sung R, Choi JW. An experimental model of hepatic fibrosis induced by alcohol and CCl4: can the lipopolysaccharide prevent liver injury induced by alcohol and CCl4? Taehan Kan Hakhoe Chi 2002; 8: 173-178.
16. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006; 26: 8-22.